ST. PAUL, Minn.--(BUSINESS WIRE)--Torax Medical announced today the forthcoming completion of a second 5-year clinical trial for the LINX procedure to treat gastro-esophageal reflux disease (GERD). Previous reporting of safety and efficacy for this pivotal trial provided the scientific evidence necessary for FDA approval for the LINX device in early 2012.
“Completion of this pivotal trial is a momentous achievement for the study investigators. The vigilance necessary to perform a study of this magnitude is significant and critical for the advancement of minimally invasive surgery,” commented Dr. Tom R. DeMeester, Chairman of the Medical Advisory Board for Torax Medical and Chairman Emeritus, USC Department of Surgery. Dr. DeMeester further stated, “This new data provides an essential basis for the long-term durability of the LINX procedure. GERD is a chronic condition and needs a minimally invasive treatment option like LINX, when the disease becomes progressive.”
Help employers find you! Check out all the jobs and post your resume.
“Completion of this pivotal trial is a momentous achievement for the study investigators. The vigilance necessary to perform a study of this magnitude is significant and critical for the advancement of minimally invasive surgery,” commented Dr. Tom R. DeMeester, Chairman of the Medical Advisory Board for Torax Medical and Chairman Emeritus, USC Department of Surgery. Dr. DeMeester further stated, “This new data provides an essential basis for the long-term durability of the LINX procedure. GERD is a chronic condition and needs a minimally invasive treatment option like LINX, when the disease becomes progressive.”
Help employers find you! Check out all the jobs and post your resume.
